TVRD
HEALTHCARECara Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving TVRD Today?
No stock-specific AI insight has been generated for TVRD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.66
Fundamentals
Trading
TVRD News
20 articles- Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business UpdateYahoo Finance·May 8, 2026
- Sector Update: Health Care Stocks Fall Late AfternoonYahoo Finance·Apr 20, 2026
- Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation SymposiumYahoo Finance·Apr 2, 2026
- Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business UpdateYahoo Finance·Mar 31, 2026
- Tvardi Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 12, 2026
- We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn RateYahoo Finance·Feb 7, 2026
- Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 8, 2026
- Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsYahoo Finance·Jan 8, 2026
- Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowYahoo Finance·Nov 18, 2025
- Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceYahoo Finance·Nov 18, 2025
- Tvardi: Q3 Earnings SnapshotYahoo Finance·Nov 13, 2025
- Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business UpdateYahoo Finance·Nov 13, 2025
- Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in LondonYahoo Finance·Nov 4, 2025
- Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock NowYahoo Finance·Oct 28, 2025
- Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a TurnaroundYahoo Finance·Oct 16, 2025
- TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key GoalsYahoo Finance·Oct 14, 2025
- AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of complianceBiopharmadive·Oct 14, 2025
- Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial ResultsYahoo Finance·Oct 14, 2025
- Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary FibrosisYahoo Finance·Oct 13, 2025
- Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26%Yahoo Finance·Oct 11, 2025
All 20 articles loaded
Price Data
52-Week Range
$3.66
Fundamentals
Trading
About Cara Therapeutics Inc
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering innovative therapies for oncology and other critical medical challenges. Utilizing its proprietary drug discovery platform, Tvardi focuses on the development of small molecule therapies that target protein degradation pathways to offer therapeutic advantages in cancer treatment. Its lead candidate, TVB-2640, is designed to undermine cancer cell survival mechanisms, showcasing the company's dedication to advancing treatment options for patients facing malignancies. With a strong pipeline and a commitment to scientific excellence, Tvardi is well-positioned to transform the cancer therapeutics arena and improve patient outcomes.